Comparative outcomes of ceftazidime-avibactam versus meropenem-vaborbactam for KPC-producing Enterobacterales infections

Antimicrobial Agents and Chemotherapy 2026 Open access

Read full text
Authors: Sara M. Karaba, Dariusz A Hareza, José M. Munita, José R W Martínez, Yehudit Bergman, Armani M. Hawes, Zackery P. Bulman, Sara E. Cosgrove, Patricia J. Simner, Pranita D. Tamma
DOI: 10.1128/aac.01602-25
Cited by: 3
References: 24

Abstract

ABSTRACT Thirty-day mortality was similar in a propensity-score-weighted cohort of 73 patients with KPC-producing Enterobacterales infections treated with ceftazidime-avibactam or meropenem-vaborbactam. Emergence of resistance was higher in the ceftazidime-avibactam group (12% vs 0%); putative resistance mechanisms included porin mutations ( Klebsiella pneumoniae ) and R2 loop structural changes in AmpC ( Enterobacter cloacae complex).

Fields of Study & Subjects

Antibiotic Resistance in Bacteria Infections and bacterial resistance Antibiotics Pharmacokinetics and Efficacy

Publication details

Journal / source
Antimicrobial Agents and Chemotherapy
Publisher
American Society for Microbiology
Volume
70
Issue
5
Pages
e0160225–e0160225
Publication date
23 March 2026
Language
EN